Zhang Na, Guo Ming-Fang
Department of Gynecologic Oncology, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, CHN.
Cureus. 2024 Feb 20;16(2):e54573. doi: 10.7759/cureus.54573. eCollection 2024 Feb.
Recurrent or metastatic cervical cancer carries a bleak prognosis and presents a formidable challenge in terms of treatment. Granulocyte-macrophage colony-stimulating factor (GM-CSF) increases the body's immune response by enhancing antigen presentation, which has been rarely reported in recurrent or metastatic cervical cancer. A 44-year-old woman presented to the hospital with vaginal bleeding four years after radical hysterectomy for stage IB2 squamous cell carcinoma (SCC) of the cervix (grade II-III). Gynecological examination and imaging revealed a vaginal mass, and the biopsy confirmed the recurrence of grade III SCC. The patient was treated with chemoradiation (CRT) combined with immunoadjuvant GM-CSF and achieved complete remission and a progression-free survival of two years.
复发性或转移性宫颈癌预后不佳,在治疗方面是一项艰巨挑战。粒细胞-巨噬细胞集落刺激因子(GM-CSF)通过增强抗原呈递来提高机体免疫反应,这在复发性或转移性宫颈癌中鲜有报道。一名44岁女性因宫颈IB2期鳞状细胞癌(II-III级)行根治性子宫切除术后四年出现阴道出血,前来我院就诊。妇科检查及影像学检查发现阴道肿物,活检证实为III级鳞状细胞癌复发。该患者接受了放化疗(CRT)联合免疫佐剂GM-CSF治疗,实现了完全缓解,并获得了两年的无进展生存期。